Liang Li1, Lizhi Zhang1, Philip F Binkley2, Wolfgang Sadee1, Danxin Wang3,4. 1. Center for Pharmacogenomics and Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 1005 BRT, 460 West 12th Ave, Columbus, Ohio, 43210, USA. 2. Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio, 43210, USA. 3. Center for Pharmacogenomics and Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 1005 BRT, 460 West 12th Ave, Columbus, Ohio, 43210, USA. wang.808@osu.edu. 4. Center for Pharmacogenomics and Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, 1005 BRT, 460 W 12th Avenue, Columbus, Ohio, 43210, USA. wang.808@osu.edu.
Abstract
PURPOSE: Protein kinase C α (PRKCA) is involved in multiple functions and has been implicated in heart failure risks and treatment outcomes. This study aims to identify regulatory variants affecting PRKCA expression in human heart, and evaluate attributable risk of heart disease. METHODS: mRNA expression quantitative trait loci (eQTLs) were extracted from the Genotype and Tissue Expression Project (GTEx). Allelic mRNA ratios were measured in 51 human heart tissues to identify cis-acting regulatory variants. Potential regulatory regions were tested with luciferase reporter gene assays and further evaluated in GTEx and genome-wide association studies. RESULTS: Located in a region with robust enhancer activity in luciferase reporter assays, rs9909004 (T > C, minor allele frequency =0.47) resides in a haplotype displaying strong eQTLs for PRKCA in heart (p = 1.2 × 10-23). The minor C allele is associated with both decreased PRKCA mRNA expression and decreased risk of phenotypes characteristic of heart failure in GWAS analyses (QT interval p = 3.0 × 10-14). While rs9909004 is the likely regulatory variant, other variants in high linkage disequilibrium cannot be excluded. Distinct regulatory variants appear to affect expression in other tissues. CONCLUSIONS: The haplotype carrying rs9909004 influences PRKCA expression in the heart and is associated with traits linked to heart failure, potentially affecting therapy of heart failure.
PURPOSE: Protein kinase C α (PRKCA) is involved in multiple functions and has been implicated in heart failure risks and treatment outcomes. This study aims to identify regulatory variants affecting PRKCA expression in human heart, and evaluate attributable risk of heart disease. METHODS: mRNA expression quantitative trait loci (eQTLs) were extracted from the Genotype and Tissue Expression Project (GTEx). Allelic mRNA ratios were measured in 51 human heart tissues to identify cis-acting regulatory variants. Potential regulatory regions were tested with luciferase reporter gene assays and further evaluated in GTEx and genome-wide association studies. RESULTS: Located in a region with robust enhancer activity in luciferase reporter assays, rs9909004 (T > C, minor allele frequency =0.47) resides in a haplotype displaying strong eQTLs for PRKCA in heart (p = 1.2 × 10-23). The minor C allele is associated with both decreased PRKCA mRNA expression and decreased risk of phenotypes characteristic of heart failure in GWAS analyses (QT interval p = 3.0 × 10-14). While rs9909004 is the likely regulatory variant, other variants in high linkage disequilibrium cannot be excluded. Distinct regulatory variants appear to affect expression in other tissues. CONCLUSIONS: The haplotype carrying rs9909004 influences PRKCA expression in the heart and is associated with traits linked to heart failure, potentially affecting therapy of heart failure.
Entities:
Keywords:
association; gene expression; genetic variant; heart failure; polymorphism; protein kinase C α (PRKCA)
Authors: Amy Murphy; Kelan G Tantisira; Manuel E Soto-Quirós; Lydiana Avila; Barbara J Klanderman; Stephen Lake; Scott T Weiss; Juan C Celedón Journal: Am J Hum Genet Date: 2009-07-02 Impact factor: 11.025
Authors: Yuefang Ma; Kanchana Usuwanthim; Usma Munawara; Alex Quach; Nick N Gorgani; Catherine A Abbott; Charles S Hii; Antonio Ferrante Journal: J Immunol Date: 2015-02-16 Impact factor: 5.422
Authors: T Rau; H-D Düngen; F Edelmann; F Waagstein; M Lainščak; S Dimković; S Apostolović; A N Nešković; W Haverkamp; G Gelbrich; T Eschenhagen Journal: Clin Pharmacol Ther Date: 2012-05-23 Impact factor: 6.875
Authors: Danxin Wang; Audrey C Papp; Philip F Binkley; Julie A Johnson; Wolfgang Sadée Journal: Pharmacogenet Genomics Date: 2006-10 Impact factor: 2.089
Authors: Elizabeth S Barrie; David Weinshenker; Anurag Verma; Sarah A Pendergrass; Leslie A Lange; Marylyn D Ritchie; James G Wilson; Helena Kuivaniemi; Gerard Tromp; David J Carey; Glenn S Gerhard; Murray H Brilliant; Scott J Hebbring; Joseph F Cubells; Julia K Pinsonneault; Greg J Norman; Wolfgang Sadee Journal: Circ Res Date: 2014-10-17 Impact factor: 17.367
Authors: Julia K Pinsonneault; Dawn D Han; Katherine E Burdick; Maria Kataki; Alessandro Bertolino; Anil K Malhotra; Howard H Gu; Wolfgang Sadee Journal: Neuropsychopharmacology Date: 2011-04-27 Impact factor: 7.853
Authors: Jasmine A Luzum; Christopher Ting; Edward L Peterson; Hongsheng Gui; Tyler Shugg; L Keoki Williams; Liang Li; Wolfgang Sadee; Danxin Wang; David E Lanfear Journal: Cardiovasc Drugs Ther Date: 2019-12 Impact factor: 3.727
Authors: Ray Hu; Michael P Morley; Jeffrey Brandimarto; Nathan R Tucker; Victoria A Parsons; Sihai D Zhao; Benjamin Meder; Hugo A Katus; Frank Rühle; Monika Stoll; Eric Villard; François Cambien; Honghuang Lin; Nicholas L Smith; Janine F Felix; Ramachandran S Vasan; Pim van der Harst; Christopher Newton-Cheh; Jin Li; Cecilia E Kim; Hakon Hakonarson; Sridhar Hannenhalli; Euan A Ashley; Christine S Moravec; W H Wilson Tang; Marjorie Maillet; Jeffery D Molkentin; Patrick T Ellinor; Kenneth B Margulies; Thomas P Cappola Journal: Circ Genom Precis Med Date: 2018-03